Name Dubai Biotechnology and Research Park.
Size: 300-hectare stretch
Location: Dubailand
Start: 2005
End: 2006 ( first stage )
Cost: Dh300 million to Dh400 million ( first stage )
TOWERS: 2 Clusters: an industry cluster and the Foundation for Research and Innovation (FRI).

http://www.tp.spt.fi/~jukarkil/uae/dubiotech2.gif
http://i36.tinypic.com/258tqbn.jpg

Dubai takes next step forward - GULF NEWS

By Manoj Nair, Staff Reporter
Dubai: Dubai will have the world's first free zone exclusively for the biotechnology industry.

Terming it the "next step forward" for Dubai in the Knowledge Age, General Shaikh Mohammad Bin Rashid Al Maktoum, Crown Prince of Dubai and UAE Defence Minister, yesterday launched the Dubai Biotechnology and Research Park.

"Dubai Biotechnology Initiative will create an ideal platform for the regional and international scientific community to interact closely with one of the sciences that is strongly linked to the Knowledge Age," said Shaikh Mohammad.

"I want the Dubai Biotechnology Initiative to be an incubator for researchers and scientists and a centre for production, creativity and development."

To be located on a 300-hectare stretch at Dubailand, DuBiotech will be developed over multiple phases.

Upon completion, the park development will cover over 30 million square feet of built-up area. Its infrastructure offering will comprise research and development (R&D) facilities, office space and residential facilities.

"I look forward to the outcome of this initiative. I have high hopes and I can clearly see its positive impact on the UAE and the whole region," Shaikh Mohammad said.

He said the Dubai Biotechnology Initiative follows in the steps of the Dubai Internet City, e-Government and Dubai Media City.

"Like them, it will spread the modern technology culture - which put the UAE on the map as a role model for the region and the world and made it a pioneer in the field of Information and Communication Technology."

"I want the Dubai Biotechnology Initiative to be a centre for civilisation and science in the UAE and to benefit the wider world."

The first phase of development of DuBiotech will be ready by early 2006.

http://www.gulfnews.com/Articles/BusinessNF.asp?ArticleID=150299

GULF NEWS Published: 2/2/2005, 08:21 (UAE)
DuBiotech to include two clusters

By Manoj Nair, Staff Reporter
Dubai: The Dubai Biotechnology and Research Park will comprise two main initiatives - an industry cluster and the Foundation for Research and Innovation (FRI).

The project was launched yesterday by General Shaikh Mohammad Bin Rashid Al Maktoum, Dubai Crown Prince and UAE Defence Minister.

DuBiotech will seek to attract a mix of biotechnology and pharmaceutical companies active in discovery, R&D, testing, production, storage, sales and distribution, officials said.

It will also attract companies offering business support services for this industry such as legal and venture capital (VC) firms specialising in the biotech industry, educational and training institutions focused on biotech, and equipment, materials and consumables suppliers.

"Infrastructure investments in the first phase will total Dh300 million to Dh400 million," said Ahmad Bin Byat, director-general of the Dubai Technology and Media Free Zone.

The Foundation for Research and Innovation (FRI) will be a specialised organisation focusing on government-funded research and development in select fields like medical genetics, plant biotechnology encompassing food and agriculture, environmental and equine-related biotechnology, drug discovery, pharmaceutical research, stem cell research, infectious diseases and forensic research.

Incubator facilities within the foundation will also aid new projects develop into productive and profitable ventures.

"Our aim is to accelerate the region's biotechnology industry," Bin Byat said. "The new park will create the ideal conditions for encouraging scientific research and production in the biotech industry.

"DuBiotech is also part of Dubai's next growth horizon and its long-term plan of creating a strong diversified knowledge-based economy."

DuBiotech will be headed by Dr Abdulqader Al Khayat, who left his position as director-general of Dubai Police's General Department of Forensic Administration to take over as executive director of the new initiative.

The park will have a regulatory framework, modelled on international best practices, he said.

The key focus of the regulations will be on upholding the highest ethical, environmental, health and safety standards.

DuBiotech will also develop comprehensive guidelines to ensure this.

"DuBiotech seeks to provide a long-term view for the region by providing not just for the next generation but the generations that will follow it," said Dr. Alkhayat.

"The initiative is more than an economic venture and will have a strong social focus."

To encourage new ventures, DuBiotech will have a system in place that will provide funding and financial assistance to research initiatives, incubators and joint projects.

An investment committee will be set up to make funding decisions after conducting due diligence on business plans.

Members of the park can take advantage of of a host of support facilities and services.

Areas have been set aside for companies who wish to construct their own buildings.

Dedicated production, warehousing and distribution areas will be created. Clean rooms, vivariums and specialised equipment will be available.

Other facilities will include a library, video-conferencing, auditorium, theatre, meeting rooms, rest-aurants, retail banking and mailroom.

Also planned for the future are botanical gardens and a museum.

The park will also provide all the benefits enjoyed by companies in the Dubai Technology and Media Free Zone.

They include 100 per cent exemption on corporate and personal tax guaranteed by the Dubai Government for 50 years, 100 per cent ownership of their business, full repatriation of capital and profits, no currency restrictions, a one-stop-shop of support services, simplified incorporation and a fast-track visa service.

DuBiotech will build affiliations and partnerships and pursue collaboration with renowned universities, specialised medical institutions, international NGOs and other leading biotechnology parks and clusters.

The park will work closely with academic institutions in the UAE and elsewhere in the GCC.

made this into a thread !

Mohammed launches biotech park project

DUBAI — In another unprecedented move to tap the bio-technology industry, General Shaikh Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and UAE Defence Minister yesterday announced the launch of a multi-million Dubai Biotechnology and Research Park (DuBiotech), the world's first free zone dedicated to the biotechnology industry.


The first development of DuBiotech will be ready by early 2006. Upon completion, the park development will cover over 30 million square feet of built-up area. Its infrastructure offering will comprise of custom-made research and development (R&D) facilities.

DuBiotech will create a comprehensive infrastructure and environment to develop biotechnology in the region. The park will be built in several phases on a 300 hectare area located close to the Dubailand project. The idea of launching the project hatched up during the Group of 77 Conference on Science and Technology held in Dubai in 2002.

Shaikh Mohammed said, "We have been working very hard on taking our country and society to the knowledge age. It is a historic transformation as it entails reconsidering all our activities, regulations, rules for work and education as well as the structure of our government and economy."

He added, "We have taken all the necessary actions and we are progressing on our journey. We have been challenging ourselves, and challenging time and have successfully made it, as we have built the solid foundations required for this transformation. We now have a well developed electronic infrastructure that compares well with similar infrastructures in the developed countries. Our economy has now become a modern economy, which relies on advanced technology."

"This has resulted in a great boost for the gross domestic product, achieving high levels of growth, increasing direct foreign investments, and reinforcing the standing of the UAE in the region and the world," said Shaikh Mohammed. However, in spite of all what we have successfully achieved, we are still at the beginning of the road."

"This might sound modest, but we truly are still at the beginning of the road. We have a long way to go for which we need more effort, more work, and more rapid achievement."

"Today, we take a new step forward in this regard by launching the 'Dubai Biotechnology Initiative'," Shaikh Mohammed added. It is impossible to progress in this age without directly incorporating biotechnology. This is exactly what we aim to achieve by launching the 'Dubai Biotechnology Initiative'. It will serve as another pillar in our edifice of knowledge that benefits both the society and the economy." Shaikh Mohammed said.

"I look forward to the outcome of this initiative. I have high hopes and I can clearly see its positive impact on the UAE and the whole region. Dubai Biotechnology Initiative follows in the steps of Dubai Internet City, e-Government and Dubai Media City, he added.

"I want the Dubai Biotechnology Initiative to be an incubator for researchers and scientists and a centre for production, creativity and development. And, in order to achieve that, we will ensure a suitable environment and the basic infrastructure that will attract the best scientists, research centres and biotechnology laboratories."

Ahmad Bin Byat, Director General of the Dubai Technology and Media Free Zone, said, "Our aim is to accelerate the region's biotechnology industry."

"The new park will create the ideal conditions for encouraging scientific research and production in the biotech industry. DuBiotech is also part of Dubai's next growth horizon and its long-term plan of creating a strong diversified knowledge-based economy," he added. The park will comprise two main initiatives — an industry cluster and the Foundation for Research and Innovation (FRI). As part of developing a cluster, DuBiotech seeks to attract a synergistic mix of biotechnology and pharmaceutical companies active in discovery, R&D, testing, production, storage, sales and distribution. It will also attract companies offering business support services for this industry such as legal and venture capital (VC) firms specialising in the biotech industry, educational and training institutions focused on biotech, and equipment, materials and consumables suppliers.

DuBiotech will be headed by Dr. Abdulqader Al Khayat who recently left his position as director general of Dubai Police's General Department of Forensic Administration, to take over as executive director of the new initiative. Dr. Al Khayat brings with him over 20 years of experience in the fields of genetics and forensics.

Still at the beginning of road, says Mohammad

Dubai: Excerpts from the speech from General Shaikh Mohammad Bin Rashid Al Maktoum, Dubai's Crown Prince and UAE Defence Minister:

"We have been working very hard on taking our country and society to the Knowledge Age.

"It is a historic transformation as it entails reconsidering all our activities, regulations, rules for work and education as well as the structure of our government and economy.

"We have taken all the necessary actions. We have been challenging ourselves, and challenging time and have successfully made it, as we have built the solid foundations required for this transformation.

"We now have a well-developed electronic infrastructure that compares well with similar infrastructures in the developed countries.

"Our economy has now become a modern economy, which relies on advanced technology.

"This has resulted in a great boost for the gross domestic product, achieving high levels of growth, increasing direct foreign investments, and reinforcing the standing of the UAE in the region and the world.

"However, in spite of all what we have successfully achieved, we are still at the beginning of the road.

"We have a long way to go for which we need more effort, more work, and more rapid achievement. "It is true that we are still at the beginning. But, it is the right beginning one that ensures the right direction, lays a good foundation for what comes next, and maintains the faith put in our plans for moving to the Knowledge Age.

"Today, we take a new step forward in this regard by launching the Dubai Biotechnology Initiative.

"There is no doubt that you all understand the significance of this project and the vitality of biotechnology, as it is one of the main keys to the future.

"Since the discovery of DNA, science has made great breakthroughs in the fields of health, agriculture and production. The scope of these applications is increasing every day. Biotechnology has become one of the determinants of development in the Knowledge Age.

"Thus, it is impossible to progress in this age without directly incorporating biotechnology. This is exactly what we aim to achieve by launching the 'Dubai Biotechnology Initiative'.

"It will serve as another pillar in our edifice of knowledge that benefits both the society and the economy.

"And, in order to achieve that, we will ensure a suitable environment and the basic infrastructure that will attract the best scientists, research centres and biotechnology laboratories."

However, in spite of all what we have successfully achieved, we are still at the beginning of the road.

"We have a long way to go for which we need more effort, more work, and more rapid achievement.
Talk about ambition! Seems like he has more plans to launch "Knowledge" and R&D projects in the near future. Good for Dubai.

yesm science is something which doesn't exist in dubai yet

maybe they'll launch universities soon

Mohammad meets DuBiotech board

Dubai: The Dubai Biotechnology and Research Park, conceived as the first free zone dedicated to the biotech industry, will be split into five phases, with the first to be ready by early 2006.

Shaikh Mohammad yesterday received members of the advisory board of the DuBiotech, including researchers and scientists from the UAE and other countries who helped out in conducting studies for the set up of the park, the world's first free zone dedicated to the biotechnology industry.

Shaikh Mohammad was full of praise for the efforts exerted in research that led to the establishment of the park.

"The masterplan for the first phase of DuBiotech has been finalised," said Ahmad Bin Byat, director-general of Dubai Technology and Media Free Zone, while briefing the media late on Tuesday.

Investment in infrastructure for the first phase should be Dh300 to Dh400 million.

On whether land in the new project will be offered for sale or as long-term lease, the official said: "We are open to any suggestion from the investors.

"All prospective investors will have to go through an extensive screening process before agreements are finalised.

"We have to determine whether the kind of expertise they bring in can fill a regional requirement as well."

Bin Byat said the issue of subsiding land for investors would also depend on the type of projects that are proposed.

Mohammed meets biotech park panel

3 February 2005

DUBAI - General Shaikh Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and UAE Defence Minister, received in Dubai members of the advisory board of the Dubai Biotechnology and Research Park panel (Dubiotech), including researchers and scientists from the UAE and other countries who helped out in conducting studies for the set up of the park, the world’s first free zone dedicated to the biotechnology industry.

The Dubai Crown Prince was full of praise for the efforts exerted in research that led to the establishment of the park.

Meanwhile, General Shaikh Mohammed received here on Tuesday night Frankfurt’s Mayor Petra Roth.

They exchanged views on avenues of cooperation between the UAE and Germany in general and Dubai and Frankfurt in particular, with special emphasis on culture, tourism and trade.

During the meeting, Gen. Shaikh Mohammed stressed the importance of bolstering cooperation and friendship between nations in an endeavour to reach a homogeneous cultural blend.

Roth, who is leading a high level delegation including the chairman of Frankfurt Chamber of Commerce and Industry, hailed the level of existing cultural, tourist and investment cooperation between the two countries, especially among private sectors.

She further praised “the qualitative progress and impressive world class achievements” made in various sectors in the UAE, citing development projects in Dubai as an example.

thats great!

300 hectare set aside for world’s first biotechnology free zone


Dubai has earmarked 300 hectares of land for the development of the world’s first free zone dedicated to the biotechnology industry. The Dubai Biotechnology and Research Park (DuBiotech) project was announced by General Sheikh Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and UAE Defence Minister.

DuBiotech will create the infrastructure and environment in which to develop the region’s biotechnology sector. The park will be built in several phases
on a 300-hectare site, close to the Dubailand project.

“We have been working hard to take our country and society into the ‘knowledge age’. In spite of all that we have successfully achieved, we are still at the beginning of the road. Today, we take a new step forward — by launching the Dubai Bio-technology Initiative,” commented Sheikh Mohammed.

Dubai Biotechnology initiative is to be an incubator for researchers and scientists and a centre for production, creativity and development. Upon completion, the park will cover more than 3 million m2 of built-up area. Its infrastructure will comprise custom-built research and development facilities such as laboratories, sterile rooms and incubators, as well as office space and residential facilities. The first phase of development will be ready by early 2006.

Ahmad bin Byat, director general of Dubai Technology and Media Free Zone (Tecom), said that DuBiotech is part of Dubai’s next growth horizon and its long-term plan of creating a strong diversified knowledge-based economy.

The park will be built with two main segments: an industry cluster and a complex that will house the Foundation for Research and Innovation — a specialised organisation focusing on government-funded research and development in select fields.

DuBiotech will be headed by Dr. Abdulqader Al Khayat, who left his position as director general of Dubai Police’s general department of forensic administration, to take over as executive director of this new initiative. Dr. Al Khayat brings with him over 20 years’ experience in the fields of genetics and forensics.

“We are confident that DuBiotech will become the centre of excellence for biotechnology in the region. We will achieve this by creating the right business and regulatory environment, developing state-of-the-art scientific facilities, securing government funding, and maintaining an unwavering focus on developing R&D within the region,” he said.

The park will offer 100% exemption on corporate and personal tax — guaranteed by the Dubai Government for 50 years — 100% ownership of the business, 100% repatriation of capital and profits, no currency restrictions, simplified incorporation, and a fast-track visa service.

I'd have to say the Mohamed Alabbar is the personality I admire most in dubai, such an influential,innovative and hard working character.



Alabbar launches two Dubai-based companies in stem cell research and robotic surgery with global bio-medicine pioneer Dr. Lim
Mohamed Ali Alabbar, the Director General of the Government of Dubai's Department of Economic Development, today announced the launch of two groundbreaking initiatives involving cutting edge research into stem cell technology and robotic surgery to be set up in Dubai.



http://www.ameinfo.com/images/news/3/11873-alabbar-and-dr-lim.jpg
Mr. Alabbar and Dr. Susan Lim

Mr. Alabbar signed a memorandum of understanding with Singapore-based bio-medicine pioneer Dr. Susan Lim, at the four-day Arab Health Exhibition and Congress which opened here today, to set up Dubai Stem Cell Technologies i (DSCTi) and the Dubai Centre for Robotic Surgery (DCRS).

The location of the two initiatives in Dubai, which will be home to the world's first biotechnology free zone, is a huge step forward for next generation biotechnology and healthcare research in the Middle East region. The signing follows the recent announcement of the US$100 million, 300 hectare Dubai Biotechnology and Research Park (DuBiotech).

The launch of DSCTi and DCRS is in line with the vision of His Highness General Sheikh Mohammed Bin Rashid Al Maktoum, Crown Prince of Dubai and UAE Defence Minister to place the emirate at the cutting edge of biotechnology and life sciences research and development. These initiatives will lead to Dubai becoming a leading centre for biotechnology and healthcare excellence.

Mr. Alabbar, who is chairman of DSCTi and DCRS, said: 'I am very pleased to welcome Dr. Susan Lim and her team to begin their groundbreaking work in Dubai. She is a very special addition to Dubai and is credited with conducting the first liver transplant and the first robotic surgery in Asia.

'The launch of the two companies signals that we are on the verge of seeing an entirely new approach to medicine take root in the region. These two companies will extend our capabilities in healthcare research and development. The new discipline of robotic surgery will bring immediate benefits to patients in the region. I invite the regional medical fraternity to become a part of this work and learn from it,' Mr. Alabbar said.

The specific mission of DSCTi, is to derive differentiated cell types primarily from Adult Stem Cells for use in cell replacement therapies. The facility in Dubai will act as an incubator for research scientists and a centre for creativity and development.

The aim is to develop a robust human adult stem cell technology platform and new patents and build up an intellectual property portfolio. The immediate goal of the DSCTi is to begin conducting clinical trials with its first therapeutic differentiated adult stem cell lineage before 2009.

DCRS will be the first robotic surgery-capable institution in the region and will offer all the benefits of the technology, including minimum invasiveness, early recovery times and precision. It will provide the region's population with immediate access to a state of the art robotic surgery facility in their own country.

Speaking on the need to focus on research and innovation, Mr. Alabbar said: 'Over the last 20 years the Arab World, in comparison with other economies, has been slow to invest in new technologies resulting in a very low percentage of gross national product invested on scientific research.

'Such initiatives will be a beacon for other countries to invest further in frontier technologies with bear rich potential rewards for the Middle East and also more job opportunities for our best research scientists.'

Dr. Lim, CEO of DSCTi and DCRS, said: 'I would like to thank Mr. Alabbar for his support and encouragement in setting up DSCTi and DCRS in Dubai. His guidance, leadership and support will be critical in realising the overall vision of Dubai Centre for Robotic Surgery and Dubai Stem Cell Technologies i.

'In making this commitment to Dubai, the research facility will have immediate access to a team of international scientists who are authorities in their respective fields of stem cell biology and robotics surgery.'

Positive spin-offs from the work of DSCTi will include the use of stem cells to yield insulin-producing cells to cure diabetes, combat central nervous system disorders such as Lou Gehrig's and Alzheimer's diseases, and treat injuries and diseases that afflict the aged. It will have immediate access to the laboratories at the National University of Singapore (NUS), which boast world class facilities in stem cell research.

The benefits from the establishment of DCRS will be felt in related areas such as telemedicine and tele-robotic surgery and having the facility here in Dubai will attract biomedical-related companies such as surgical instruments providers, designers, and businesses involved in training and consumables integral for robotics. The activity that will result from it should confirm Dubai as the region's biotechnology hub.

DSCTi and DCRS will identify promising young scientific talent from the UAE and train the best in its facilities in Singapore. This next generation of scientists will be able to conduct their own research and initiate projects. This will support the strategy of forging partnerships and collaborations with global leaders in both areas of research.

Two firms in medical tech launched


13 February 2005


DUBAI - Mohamed Ali Alabbar, the Director General of the Government of Dubai's Department of Economic Development, yesterday announced the launch of two initiatives involving research into stem cell technology and robotic surgery in Dubai.

He signed a memorandum of understanding with Singapore-based bio-medicine pioneer Dr Susan Lim, at the four-day Arab Health Exhibition and Congress which opened here yesterday to set up Dubai Stem Cell Technologies i (DSCTi) and the Dubai Centre for Robotic Surgery (DCRS).

The location of the two initiatives in Dubai, which will be home to the world's first biotechnology free zone. The signing follows the recent announcement of the $100 million, 300 hectare Dubai Biotechnology and Research Park (DuBiotech). “The launch of the two companies signals that we are on the verge of seeing an entirely new approach to medicine take root in the region. These two companies will extend our capabilities in healthcare research and development. The new discipline of robotic surgery will bring immediate benefits to patients in the region. I invite the regional medical fraternity to become a part of this work and learn from it,” said Alabbar.

The specific mission of DSCTi, is to derive differentiated cell types primarily from Adult Stem Cells for use in cell replacement therapies. The facility in Dubai will act as an incubator for research scientists and a centre for creativity and development.

The aim is to develop a robust human adult stem cell technology platform and new patents and build up an intellectual property portfolio. The immediate goal of the DSCTi is to begin conducting clinical trials with its first therapeutic differentiated adult stem cell lineage before 2009.

DCRS will be the first robotic surgery-capable institution in the region and will offer all the benefits of the technology, including minimum invasiveness, early recovery times and precision.

It will provide the region's population with immediate access to a state of the art robotic surgery facility in their own country.

I think its a great project. But im not sure about Dubailand, when you think of Dubailand you think of Disney land, not a place for a research center of this level. I think Dubai should seriously think about launching some sort of Education or research zone. And area with two private school and rip-off international "universities" and calling it education whatever wont do it.
Hopefully in the near future will hear of such a project.

I dont like the idea of having a "Biotechnology Free Zone". I mean there's a limit to these things and they should remain under the govt's control. What if they want to start cloning tomorrow in Dubai???

Also, someone please explain why Dubai is supporting Stem Cell research??? I dont know about Islamic point of view on this matter but it's clearly against the ethics of the UAE. I really dont think this would happen under Shkh Zayed. Such a pity. Stem-cell reserch was the only point I supported Bush on in the elections!!

http://www-camlaw.rutgers.edu/publications/law-religion/new_devs/RJLR_ND_56.pdf

I would urge people not to comment on Islamic ethics without any background information on the subject. Stem cell research is Islamically acceptable and has been approved by several fiqh councils if certain conditions are met.

Thank you, and you will not hear of this again.

I really have nothing to add, i just felt the urge to put in something.

I would urge people not to comment on Islamic ethics without any background

I am a Muslim and am proud to be a Muslim. I do have knowledge about Islamic ethics. However, stem cell research is a new subject which is relevant mostly to the current generation and hence there can be more than one religious view point on this matter.

DuBiotech announces steering committee

The Dubai Biotechnology and Research Park (DuBiotech) has announced a steering committee comprising eminent biotechnology experts that will offer strategic guidance to the new initiative.

The steering committee will advise the DuBiotech management on initiatives to support and foster the growth of the biotechnology industry in the region and enable DuBiotech to respond to new challenges and opportunities in the sector.

Specifically, the committee will look at ways to boost the biotechnology industry through technology transfer and support for new ideas and discoveries. It will recommend ways of enhancing biotech research and developing DuBiotech into an attractive location for "life sciences" companies.

check the masterplan of this project on http://www.dubiotech.com/

path: ABOUT US / DUBAI BIOTECHNOLOGY & RESEARCH PARK

wow, nice plan
you can put these to first post
http://www.tp.spt.fi/~jukarkil/uae/dubiotech2.gif
http://www.tp.spt.fi/~jukarkil/uae/dubiotech.gif
hmmh, if you look closely there seem to be large shadow from skyscraper in the middle of area, in nucleus park :)

Lol maybe all the scientist in the world can fit in that place :D

yeah its HUGE!

Pharmaceutical industry in Dubai is estimated at Dh2b

20 March 2005

DUBAI — The pharmaceuticals industry of Dubai is estimated at Dh2 billion and with the latest launch of Dubai Biotechnology and Research park (DuBiotech) by the Government of Dubai and Dubai Healthcare City, this figure is set to increase manifold in the coming future, according to analysts.

The DuBiotech to be built on a 300-hectare area located close to Dubailand project will create a comprehensive infrastructure and environment to develop biotechnology in the region.

As part of its development, DuBiotech will try to attract a mix of pharmaceutical companies active in discovery, research and development, testing, production, storage, sales and distribution.

The pharmaceutical market is set to grow by more than 12 per cent each year due to huge domestic demand, increased privatisation, increasing population and simplification of regulations governing the industry as well as high standards of living, according to statistics.

Moreover, the government is also a major buyer of pharmaceutical products and the ministry of health has an annual budget of more than Dh200 million for drugs and chemicals. The demand for medications account for almost 90 per cent of the entire imports and the largest category of imported medicines fall in the general category.

New companies, like Neopharma have set production facilities and its plant has the capacity to manufacture 280 million tablets, 160 million capsules and 44 million bottles of syrup, spread across 100,000 square kilometre area, and have products licenses from some of the leading pharmaceutical companies.

According to B R Shetty, managing director of Neo Pharma, “Neopharma is entering into strategic alliance with Biocon, the largest Biotech company in India and this alliance is expected to provide Neopharma with a strong platform for the manufacturing and marketing of 'Recombitant Human Insulin.’’

According to sources, Novartis Pharma services which have an eight per cent market share in the UAE are doing a lot of licensing and looking for untapped market of contract manufacturing in the UAE. Actually, Novartis is already reviewing the potential of joint venture with medical organisations in the Dubai Healthcare City (DHCC). In the UAE, the pharmaceutical industry will benefit from the re-export market, as Iran and Pakistan are major buyers of re-exported pharmaceuticals from the UAE. Apart from this, Yemen and Somalia are also major buyers of medicines from the UAE.

The UAE's export policy also helps promote products in a huge market, stretching to the neighbouring countries, the sub-continent and Commonwealth countries and opportunities will increase year on year as regional players are attracting foreign investors to use the region as abase for the wider MENA region. At present, exports are increasing in the AGCC countries followed by Sudan, Lebanon, Egypt and Bahrain. According to a leading pharmaceutical company, if the MNCs and local companies merge together and form joint venture companies than there will be intense competition on quality and price and increase the growth of pharmaceutical companies as Dubai has huge potential as export and re-export centre. Johnson & Johnson is trying to develop a surgical institute in DHCC and explore the possibilities of establishing its Middle East headquarters in Dubai.

In the next few years, demand will increase as the UAE offers excellent infrastructure facilities to investors and the Dubai BioTechnology park and the Dubai Healthcare city are likely to attract major pharmaceuticals and research companies to the UAE.

DuBiotech commits to international regulatory standards

The head of DuBiotech, Dubai's new free zone dedicated to biotechnology, has outlined the importance of industry-specific regulatory standards and infrastructure required for companies from the biotechnology industry to establish successful operations.


The life sciences sector requires not only specific laboratory designs, but also locations and support infrastructure, including biosafety and waste management support, in order to do business.

The Director of DuBiotech, Dr. Abdulqader Al Khayat outlined his views at the Dubai International Pharmaceuticals and Technologies Exhibition (DUPHAT) that concluded in Dubai yesterday.

'Today, businesses can come to Dubai very easily and start work. However, for specialised businesses that produce medicines and highly developed life sciences products and services, there is a need to establish regulatory frameworks based on international best practices and demonstrate world-class standards of hygienic and sterile environments in the region,' said Dr. Al Khayat, Executive Director of Dubiotech - the Free Zone dedicated to the biotechnology industry.

'Biotech companies require specific locations in which it's not only suitable, but also appropriate to conduct their daily business activities. It's also natural for biotech companies to congregate within specific science parks, which contribute towards business partnerships and sharing of industry experience.'

At the DUPHAT exhibition, Dubiotech exhibited and demonstrated its capabilities to handle the exacting requirements of the biotechnology and pharmaceutical industries. The requirements for the scientific community are very specialised and flourish best within facilities that are 'biotech-friendly'.

'While some alternate sites may seem attractive in the short term, it's important to consider additional unseen costs, such as retrofitting existing buildings to handle biosafety requirements, as well as being sited close to industrial, environmental and noise pollution; all of which could have detrimental consequences on their facilities.'

'We are working closely with the Dubai Municipality and the Department of Health and Medical Services (DOHMS) to ensure that the correct business ecosystem is in place from which our Business Partners can successfully develop their operations,' explained Dr. Al Khayat.

Dubiotech will be following international standards required to develop state of the art facilities for all sectors of the life sciences industry.

Maybe this story below will help BioTech Research Park create Dinosaur Park in DubaiLand! :)

"Scientists could turn Jurassic Park fiction into fact after extracting what look like blood vessels and cells from a Tyrannosaurus rex, it was disclosed yesterday.

They have not ruled out the possibility of obtaining dinosaur DNA from the 70-million-year-old samples.

Until now the idea of DNA being preserved in ancient dinosaur fossils has not been taken seriously.

But it formed the basis of Michael Crichton's novel Jurassic Park - made into a film by Steven Spielberg - in which scientists recreated dinosaurs from their DNA.

The highly preserved fossil skeleton of the T rex was unearthed in 2003 from a site in Montana in the United States.

Scientists examined one of the creature's thigh bones and noticed unusual features in the marrow cavity.

Dissolving the fossil mineral deposits with acid left a flexible, stretchy material threaded with what appeared to be transparent and hollow blood vessels.

Dr Mary Schweitzer, from North Carolina State University in Raleigh, in the United States, who led the team, told the journal Science: "It was totally shocking. I didn't believe it until we'd done it 17 times."

DuBiotech to work closely with Dohms

DuBiotech, Dubai's new free zone dedicated to biotechnology, will follow the industry-specific regulatory standards and infrastructure required for companies from the biotechnology industry to establish successful operations, said the executive director of DuBiotech, Dr. Abdulqader Al Khayat at the Dubai International Pharmaceuticals and Technologies Exhibition (Duphat) that concluded recently in Dubai.

He also added: 'Today, businesses can come to Dubai very easily and start work. However, for specialised businesses that produce medicines and highly developed life sciences products and services, there is a need to establish regulatory frameworks based on international best practices and demonstrate world-class standards of hygienic and sterile environments in the region.' The life sciences sector requires not only specific laboratory designs, but also locations and support infrastructure, including biosafety and waste management support, in order to do business.

Biotech companies require specific locations in which it's not only suitable, but also appropriate to conduct their daily business activities.

It's also natural for biotech companies to congregate within specific science parks, which contribute towards business partnerships and sharing of industry experience, according to the Khaleej Times.

At the Duphat exhibition, Dubiotech exhibited and demonstrated its capabilities to handle the exacting requirements of the biotechnology and pharmaceutical industries.

'We are working closely with the Dubai Municipality and the Department of Health and Medical Services (DOHMS) to ensure that the correct business ecosystem is in place from which our Business Partners can successfully develop their operations,' explained Dr. Al Khayat.

Dubai's biotech free zone needs early flagship success: Expert

DUBAI'S DuBiotech free zone, dedicated to biotechnology, can promote invention if it seals some early-day successes, according to an expert.

Smart 21st century entrepreneurs quickly forsake going it alone and partner major corporates, British professor Sir Chris Evans said.

Speaking before his address at "Entrepreneurs in Dubai," an entrepreneurship exhibition and forum scheduled to take place in May, Evans said the traditional image of entrepreneurs now has to change.

"By definition entrepreneurs go it alone but the smart ones quickly link up with corporate partners," said the man behind Merlin Biosciences, an investment fund for small medical and bioscience research firms.

At "Entrepreneurs in Dubai" the British professor will spell out to the audience of would-be entrepreneurs and future corporate partners how "Anyone Can Do It."

Regarded as a leading biotechnology entrepreneur, he had some advice for the fledgling 30 million square foot DuBiotech free zone aimed at encouraging the growth of biotechnology in the Middle East.

"This initiative could stimulate innovation but it needs to build flagship successes early on in its life," said Evans.

"Whilst there are plenty of entrepreneurs in the biotechnology sector, although some are better than others. DuBiotech could successfully promote innovation providing the really experienced people are brought into the project early," he said.

Though Evans says today's smart entrepreneurs look for corporate link-ups, he accepts that some of the more traditional values associated with start-up pioneers are still required for the would-be tycoon.

"Good entrepreneurs are intelligent, determined, resourceful, persuasive, streetwise, energetic, creative, charming and have leadership qualities," he said.

And while citing Virgin

founder Sir Richard Branson and Microsoft billionaire Bill Gates as among his most admired business leaders for "huge successes from nothing at all," Evans had some straight talking advice for young budding business executives.

"Make sure you really understand your business and market, focus on making your specific project work and put in 100 hours a week -- no less or you'll fail," he said.

And while entrepreneurs should let their imagination run wild -- they should, he said, concentrate on the bottom line.

"Dreams are lovely but they don't pay the bills," he cautioned. "By and large entrepreneurs portray an image of being mavericks but most are focused, driven individuals with an attention to detail and a ruthless desire to win," he said.

The Middle East could take a lead in entrepreneurship promotion providing governments buy-in to their development, Evans said.

"Governments have a role to play by providing tax breaks to encourage investment, buildings and incubators. I would certainly consider setting up a company in the region if the incentives were all there and it made sense," he said.

IIR Middle East is co-organising "Entrepreneurs in Dubai" with the Mohammed Bin Rashid Establishment For Young Business Leaders.

Running alongside the forum will be a specialised exhibition of products and services aimed at the SME sector.

DuBiotech needs to evolve as a global brand, says expert

Staff Report

Dubai:
Dubai's DuBiotech free zone must attract top biotechnology experts to begin building a strong global brand, a British biotech expert has said.

"DuBiotech could successfully promote innovation, providing really experienced people are brought into the project early," Christopher Evans. He is the founder of Merlin Biosciences, one of Europe's largest and most successful investment funds for small medical and bioscience research firms.

DuBiotech is a 30 million square foot free zone dedicated to encouraging the growth of Dubai's budding biotechnology industry.

Evans will speak about his success as an entrepre-neur at the upcoming 'Entrepreneurs in Dubai'.

Representatives of IIR Middle East, which is co-organising Entrepreneurs In Dubai along with the Mohammad Bin Rashid Establishment For Young Business Leaders, believe Evans' commitment is something of a coup for the headline event. "This is a man corporate Arabia and its financing sector can learn much from," said Jessica Sutherland, general manager of IIR Middle East. "Sir Christopher is known throughout Europe for his contribution to entrepreneurship. He has won numerous awards, prizes and medals for his many scientific and business achievements. Merlin Biosciences has built about 35 companies," she said.

"By definition, entrepre-neurs go it alone, but the smart ones quickly link up with corporate partners," Evans said. "Good entre-preneurs are intelligent, determined, resourceful, persuasive, streetwise, energetic, creative, charming and have leadership qualities."

Evans will share the Entrepreneurs in Dubai platform with more than 30 international and regional business leaders, including Donald Trump, the real estate baron. Trump will participate via video cast.

Entrepreneurs in Dubai is being held under the patronage of Shaikh Hamdan Bin Mohammad Bin Rashid Al Maktoum, Chairman of the Board, Mohammad Bin Rashid Establishment For Young Business Leaders. The Establishment provides assistance to UAE nationals who wish to create their own small- and medium-sized enterprises.

Merlin chief to speak on his success story

Christopher Evans, founder of Merlin Biosciences, one of Europe's largest and most successful investment funds for small medical and bioscience research firms, will address Entrepreneurs in Dubai.
Evans will speak about his success as an entrepreneur. He will share the Entrepreneurs in Dubai platform with more than 30 international and regional business leaders.

DuBiotech awards master plan contract to Parsons

The Dubai Biotechnology and Research Park (DuBiotech), Dubai's free zone dedicated to the biotechnology, pharmaceutical and life sciences sectors, has announced that the master plan for its park will be designed by Parsons, a leader in biotechnology manufacturing engineering, construction management and technical solutions.

http://www.ameinfo.com/images/news/9/14269-drbio.jpg
Dr. Abdulqader Al Khayat, Executive Director of DuBiotech.
Parsons will partner with CUH2A, the world's largest professional services firm dedicated to planning and design of science and technology facilities, to support the development of the DuBiotech master plan.

Established under the Dubai Technology and Media Free Zone Authority, DuBiotech will create a comprehensive infrastructure and environment to develop biotechnology in the region. The park will be built on a 300 hectare area located close to the Dubailand project.

The scope of work for Parsons is to design the master plan for a mixed-use zone that will support a biotechnology industry hub. This will include the design of the underlying support infrastructure required for the park, such as electricity, water and communications. Parsons will also provide an environmental impact statement and conduct traffic analysis within the site and the surrounding area.

A DuBiotech team led by Dr. Abdulqader Al Khayat, Executive Director of DuBiotech, is meeting with senior officials from Parsons and CUH2A this week as part of an extensive business mission to the US, UK and Europe

'As part of our ongoing efforts to prepare the groundwork for our Business Partners to expand the biotechnology industry at DuBiotech, we are looking to work closely with Parsons and CUH2A to establish a world-class infrastructure that will handle the diverse requirements of the biopharma industry. We will be meeting with senior managers of various companies with biotech expertise to study best practices and standards that we could implement within DuBiotech,' explains Dr. Abdulqader Al Khayat.

The DuBiotech team will also explore how best to ensure the accreditation of qualitative transparent regulatory practices within DuBiotech. While in the US, UK and Europe, the team will meet with organisations such as The Research Triangle Institute (RTI) and New York University.

DuBiotech has already announced its commitment to create a regulatory framework, modelled on international best-practices for the park. The key focus of the regulations will be on upholding the highest ethical, environmental, health and safety standards.

DuBiotech's business mission will end with a visit to the UAE German Economic Partnership Forum in Essen, Germany where Dr. Al Khayat will be delivering a keynote speech. DuBiotech will also be showcasing the mega project. In addition, the Forum will serve as a valuable opportunity to meet international players in the biotech industry.

Over the next few months, DuBiotech will be actively working to establish and promote links with the global biotech community. DuBiotech will forge affiliations and partnerships and pursue collaboration with renowned universities, specialised medical institutions, international NGOs and other leading biotechnology parks and clusters.

i know this man personaly ... he worked hard on this project in the last couple of years :)

i know this man personaly ... he worked hard on this project in the last couple of years :)

months u mean.

months u mean.
nah years i guess it took him 2-3 years btw he was in Dubai police

Dubai biotech zone master plan soon

Staff Report

Dubai: Work on Dubai's biotechnology freezone is expected to commence in less than two months to enable it to become operational in 18 months, said its top official yesterday.
"We have a conceptual masterplan which is being finetuned. We hope to announce the final masterplan in July after which work can commence on the infrastructure," said Dr Abdul Qader Al Khayat, DuBiotech executive director.

Dr Khayat outlined the freezone's progress at the Business in Biotechnology Symposium organised by DuBiotech at the Knowledge Village.

An International panel of experts also presented their perspectives on regulations and business strategies in the biotech industry.

Established in February this year under the Dubai Technology and Media Free Zone Authority, DuBiotech will provide comprehensive infrastructure and environment to develop biotechnology in the region.

The park will be built on a 300 hectare area located close to the Dubailand project.

Dr Khayat said the project was launched with three aims to attract and nurture the pharma and biotech companies, to encourage research and development through the establishment of a research foundation and to draw up a strong framework of regulations and best practices.

"Research and development expenditure not only in the UAE but by the Arab countries in the region as a whole is almost negligible," he said.

"There has been a reluctance to invest in projects in an industry where the returns on investments is 10 to 15 years," he said.

"Part of our role is to ensure and encourage government agencies and others to invest in research and to help identify the areas," said Dr Khayat.

"We are also exploring the possibilities of having a graduate programme and are in discussions with different educational institutions in Dubai," he said.

DuBiotech has attracted serious enquiries but it is too early yet to announce them, said a spokesman.

Dr Khayat said two US companies, Parsons and CUH2A, will develop the DuBiotech master plan.

Parsons is a leader in biotechnology manufacturing engineering, construction management and technical solutions. CUH2A is the world's largest professional services firm dedicated to planning and design of science and technology facilities.

The scope of work for Parsons is to design the master plan for a mixed-use zone that will support a biotechnology industry hub.

This will include the design of the underlying support infrastructure required for the park, such as electricity, water and communications.

GO_DUBAI :)

this is a huge mega proyect really a winer I just hope that the lab animals dont sufer unnecesary pain

HH Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Education and Chairman of the Higher Colleges of Technology and HE Mohammed Al Gergawi, CEO of Dubai Holding, yesterday signed a Memorandum of Understanding (MoU) to work together to provide the Business Partners of Dubai Biotechnology and Research Park (DuBiotech), Dubai's Free Zone dedicated to the biotechnology, pharmaceutical and life sciences sectors, with the capability to conduct research using IBM's Blue Gene supercomputer.

http://www.ameinfo.com/images/news/0/18170-mou.jpg

Mr Gergawi signed the MoU on behalf of DuBiotech and Sheikh Nahyan signed on behalf of the Centre of Excellence for Applied Research and Training (CERT), the leading technology and research organisation of the United Arab Emirates (UAE).

Under the terms of DuBiotech's agreement with CERT, DuBiotech will tap into 5.7 Teraflops of supercomputing power (equivalent to 5.7 trillion mathematical operations per second) provided by the Blue Gene system at CERT. This mammoth capacity will be made available to Business Partners at DuBiotech to conduct life science research. The agreement, announced at the IBM stand at Gitex 2005, means that Business Partners engaged in biotechnology research and development at DuBiotech will have the opportunity to make use of CERT's supercomputing centre.

'This immensely powerful supercomputer is normally used in astronomy, academic and life science research involving proteomics and protein interactions requiring significant computing power. This represents a unique opportunity for DuBiotech and CERT to boost biotechnology research for the Middle East,' says Dr Abdulqader Al Khayat, Executive Director of DuBiotech. 'This further benefits the leaders in biotechnology who are looking to develop new advances that counter medical issues prevalent in the Gulf, such as Thalassemia, Diabetes, Anaemia and Cancer.'

As well as benefiting the biotechnology sector, the announcement heralds the arrival in the region of the first such supercomputer of its kind, as this technology has been previously deployed only in Europe, the US and Asia.

'CERT intends to offer supercomputing services on demand to research institutions, colleges, universities, government and private sector companies with large data processing requirements. With the explosion of information there is a corresponding imperative to process at the Teraflop performance level offered by the Blue Gene. CERT will provide access to the only Blue Gene computer in the entire South Asia, Middle East, North Africa region.' says Dr. Robert Richards, Chief Executive Officer of CERT.

In computers, FLOPS are FLoating-point Operations per Second. A Floating-point is, according to IBM, "a method of encoding real numbers within the limits of finite precision available on computers." Using floating-point encoding, extremely long numbers can be handled relatively easily. A teraflop is equivalent to a trillion computing calculations per second.

Just watched the video and this is something REALLY IMPRESSIVE!!! Never realised this thing's so huge. :eek::eek:

More jobs for nationals i hope !

are you talking about the walkthrough on their website

yes, nicely done

and a perfect project to diversify the economy

and a project which can exist without high-rise buildings!!!

I like those DNA sculptures in the middle too

Dubai and Frankfurt unite efforts to boost biotech in the Middle East

In the presence of Mr. Roland Koch, Prime Minister of the state of Hessen in Germany, Ahmad bin Byat, Director General of Dubai Technology and Media Free Zone and Dr. Christian Garbe, Managing Director of the Frankfurt Biotechnology Innovation Center (FIZ), today signed a Memorandum of Understanding between Dubai Biotechnology and Research Park (DuBiotech) and FIZ to jointly develop in life sciences research, education, professional training, and the development of marketable products in the health sector.

'This agreement enables DuBiotech to create a marketplace of ideas producing scientific innovations for the Middle East. Furthermore, FIZ's partnership with DuBiotech indicates the opportunities DuBiotech offers to the rest of the world,' says Dr. Abdulqader Al Khayat, Executive Director of DuBiotech.


'With this cooperation, we will expand our worldwide network and secure further access to research knowledge and emerging markets. The cooperation with the United Arab Emirates represents a great opportunity for German and European enterprises in the sector of life sciences and healthcare to open up new markets in the Middle East and will enable them to bring together resources for groundbreaking and profitable projects,'


says Dr. Christian Garbe, Managing Director of the Frankfurt Biotechnology Innovation Center (FIZ).

The recent opening of the Dubai International Financial Exchange (DIFX), the first international stock exchange in the Middle East, helps in creating an excellent framework for the engagement of foreign investors that will no doubt facilitate DuBiotech's task of accelerating the development of Dubai's biotechnology industry.

german? :ohno:

when it comes to innovation germany is quite good
the political situation blocks a powerful progress though

i'm sure germans can help a lot here

hopefully it will be a project with many companies involved: usa, japan, china,...

lol, Dennis I was joking :D

when it comes to innovation germany is quite good


I agree with Dennis, if i was a responsible at Dubai biotech i would finance a number of German biotech university spin-off and take them to dubai in exchange of investement and this is 100 time more profitable for dubai than constructing towers.

totally agree :cheers:

there are some companies which are very innovative but most of them give away their knowledge (transrapid is a good example) or do not dare to invest too much since the economic situation in germany is pretty bullshit ;)

yup, that's the problem in germany
no investments at all, no progress, no development, no growth, no nothing
bureaucracy and laws destroy and complicate everything

so, a little bit of hierarchy is always good
only democracy will lead to nowhere!

there are some companies which are very innovative but most of them give away their knowledge (transrapid is a good example) or do not dare to invest too much since the economic situation in germany is pretty bullshit ;)

yup, that's the problem in germany
no investments at all, no progress, no development, no growth, no nothing
bureaucracy and laws destroy and complicate everything

so, a little bit of hierarchy is always good
only democracy will lead to nowhere!

I would totally disagree with both of you, when taking about innovation it is about technology start up which all of them will start small in size but with a very big potential of growth.

Let me give you some example in the biotechnology area:

1) the German model of matching private capital with state funding has made Germany a leading biotech center in Europe, second only to the UK in total sales, and leading Europe in the number of life science firms (365) and annual sales increase (33%).
2) The total market is expected to increase by 53% by the year 2005 and the number of employees in core biotechnology firms to grow five-fold in the next seven to ten years.

When it comes to Business incubator Germany is known to be one of the best places in Europe.

If we are talking about investment don’t forget that number of German business angle network had increased exponentially during the last year 3 networks in 1999 in 2001 36 network and in 2002 40 network of business angel network.

From the side of tech start up and universities spin-off Germany is doing quit well with a number of very innovative new companies created each year.

totally agree :cheers:

that is becaue you know that I will kick your ass if you don't agree with me :D:D :jk: :jk:

Tell me some thing Lieber summsuw :D:D I’ve met lately a number of societies active in the field of biotech mainly university spin-off with solid patents from university R & D, what are their chances of obtaining some financing through DuBiotech would you recommend them to work with DuBiotech, I ask these questions because you’ve said in a previous post that you know Dr. Abdulqader Al Khayat (if I have a good memory).

that is becaue you know that I will kick your ass if you don't agree with me :D:D :jk: :jk:

Tell me some thing Lieber summsuw :D:D I’ve met lately a number of societies active in the field of biotech mainly university spin-off with solid patents from university R & D, what are their chances of obtaining some financing through DuBiotech would you recommend them to work with DuBiotech, I ask these questions because you’ve said in a previous post that you know Dr. Abdulqader Al Khayat (if I have a good memory).

lol, no I dont.

I think binDubai said so.

i guess this one is new

http://www.dubiotech.com/images/master_plan.jpg

DuBiotech partners global research leader to develop regulatory framework

The Dubai Biotechnology and Research Park (DuBiotech) announced today that it has embarked on developing comprehensive scientific and regulatory standards for biotechnology activity in the park with expertise from RTI International, one of the world's largest independent non-profit research organisations.

The regulatory framework is expected to significantly boost the budding biotechnology and life sciences industries in the region. RTI will help DuBiotech establish laboratory and operational standards adapted to the needs of Dubai and DuBiotech. The framework will address general park regulations, health and safety issues, laboratory accreditation, environment and waste management, bioethics, clinical trials, and non-clinical research as well as intellectual property. Working together, DuBiotech and RTI will also ensure that the recommended legal and regulatory framework complies with both UAE and Islamic laws and customs.

'Biotechnology opens a whole new world of economic and social possibility for the region,' said Dr. Abdulqader Al Khayat, Executive Director of DuBiotech.

'A sound regulatory framework is necessary to harness biotechnology's potential to improve health, enhance quality of life, support the environment and promote a sustainable economy. The regulations will provide a secure and encouraging environment for research and innovation, which is central to the growth of biotechnology,' he added.

'We are keen to develop a regulatory framework based on international best practices for the park, and that is why we chose RTI International as a consultant for the project. 'RTI's mission, reputation and commitment to research integrity are exactly what we were looking for in this project,' Dr. Al Khayat further said.

'We're excited to be helping an organization like DuBiotech set the stage for world-class research and development,' said Adam Saffer, Ph.D., Executive Vice President of Strategic Planning at RTI. 'As the founding tenant of Research Triangle Park, we're looking forward to the opportunity to share our knowledge and expertise to help establish DuBiotech as one of the leading research and development zones in the Middle East.'

A world leader in environment, health, and international development research and services, RTI International has nearly 50 years of experience and has completed projects in more than 120 countries. It is recognized around the world for its research excellence in the fields of health, toxicology, laboratory sciences and environmental research.

As a leading research and technical services provider for the U.S. Environmental Protection Agency, Food and Drug Administration, Health and Human Services, National Institutes of Health and numerous other government agencies, RTI has extensive experience supporting national programmes in environment and health for both government and industry.

DuBiotech hosts meeting to discuss future of clinical research in the UAE

DuBiotech, this week, hosted a meeting that brought together various players in the UAE's life sciences sector to discuss various issues and challenges related to clinical research in the UAE.
United Arab Emirates: 1 hour, 31 minutes ago

The meeting was attended by representatives of government bodies from across the UAE, medical and pharmaceutical companies, educational institutions, and other domestic and overseas organisations involved in the promotion of life sciences. Discussions covered the ethical, regulatory, social and industry-related aspects of clinical research.

Apart from DuBiotech, the organisations represented included the UAE Ministry of Health (MoH), the Department of Health and Medical Sciences (DoHMS), Government of Dubai, the Abu Dhabi General Authority for Health Services (GAHS), Dubai Healthcare City (DHCC)'s Harvard Medical School Dubai Center and the UAE University. The meeting was also attended by two US-based professional clinical research organizations and researchers from Egypt.

'Promoting clinical research is essential to grow the biotechnology and life sciences sector in the country,' said Dr. Abdulqader Al Khayat, Executive Director of DuBiotech. 'This is also key to attracting global life sciences and pharmaceutical companies to Dubai. However, the introduction of clinical research needs to be carefully planned so that we ensure global best practices and standards. Our meetings were aimed at reaching a consensus among various players in the life sciences sector on these issues,' he added.

The specific issues that were discussed include a unified regulatory framework for clinical research, ethical safeguards, patient health and safety standards, funding initiatives and the promotion of public awareness about these issues. Participants in the meeting exchanged ideas on how international professional bodies could help in certifying and setting benchmarks for clinical research companies in the UAE.

I am a Year 3 student currently studying at the University of Cardiff in the UK and I am studying Biotechnology and will hopefully gaining a BSc Biotechnology next year.
I will later continue in gaining an MSc in Biotechnology. I was really amazed at the development of Dubai Biotech and would like to become a member of this enthusiastic team when I hopefully finish my MSc. Therefore there are question that queries me which I would like if you could please answer them for me since you all live in dubai and know more information as to what is going on .
What jobs are available for candidates who hold a BSc in Biotechnology and hold a MSc in Biotechnology as in my case?
When is the final completion of Dubai Biotech so that I can apply for a job in this research?
What is the entry requirement for students such as me for gaining a job placement in Dubai Biotech?
What is the salary based for general biotechnologist holding an MSc in Biotechnology?
Could you give me any further advice in terms of gaining experiences or doing further education in the UK in order to be a suitable applicant for the job at DubaiBioTech.
And ,finally are there any jobs in the UAE for Biotechnologist in general and what is their pay?
Thank you for you co-operation
Could you please answer my questions in detail plz.

one thread about this is enough.

+ i doubt anyone will be able to give you valueable information on that sorry.

welcome to the forum btw :)

what i am basically asking is when the final complettion of Dubai Biotech takes places will they recurit any staff who hold a high expernices and educated in the field of biotechnology?
Thankz plaz answer

Huge as Always... :D

Dubai hub for top biotechnology firm
Posted: Wednesday, May 10, 2006

http://www.tradearabia.com/source/2006-05/10/Amgen.jpg

Amgen (AMGN), the world’s largest biotechnology company, has announced the opening of its regional office in Dubai.

All Amgen commercial operations activities in the Middle East and Africa (MEA) will be managed from Dubai.

Dubai will now serve as a hub for expanding Amgen’s commercial operations in this region.

The Middle East and Africa have a population of about 350 million people.

“Our intent is to be the biotech industry’s premier player in Middle East and Africa”, Amgen’s vice-president, Ugo de Francesco, told a Press conference, announcing the opening of the Dubai office.

“We want to ensure that as many patients as possible get access to our innovative therapies that address unmet medical needs in this part of the world.

“We aim at building an outstanding management, consistent growth, and positive social and economic impact on local and national communities and customers in this region.”

Amgen selected Dubai as the location for its Middle East and Africa operations because it is strategically located at the crossroads of the East and West.

“Dubai is a cosmopolitan city with a flourishing international business community and a peaceful co-existence of all ethnic groups,” said Ashraf Allam, managing director of MEA & Turkey operations.

“Therefore we look upon Dubai as the ideal choice for our MEA activities.”

The Amgen office is located in the Dubai Biotechnology and Research Park (DuBiotech), the region’s first ‘free zone’ dedicated to the biotechnology industry.

“We are delighted to welcome Amgen as one of the founding members of the DuBiotech community,” said Dr Abdulqader Al Khayat, executive director of DuBiotech.

“We are seeking to partner with global biotech giants like Amgen to accelerate the development of the industry here. Amgen’s presence will enrich the biotechnology sector in the region and contribute to its development,” he added.

DuBiotech is building an industry cluster and research hub for biotechnology companies in Dubai.

Its aim is to create a regional center of excellence for biotechnology by bridging research, education, and industry through national and international collaborations.

Amgen discovers, develops and delivers innovative human therapeutics.

A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.

Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.

Announced in February 2005, the Dubai Biotechnology and Research Park (DuBiotech) is a science and business park dedicated to the biotechnology industry, set within a ‘free zone’. DuBiotech has two arms.

The first is the Foundation for Research and Innovation (FRI) that will initially focus on government-funded R&D in medicine and genetics, plant biotechnology encompassing food and agricultural biotech, environmental biotech and equine-related biotechnology.

Other areas include drug discovery, stem cell research, infectious diseases and forensic research.

The second arm of DuBiotech aims to set up a biotechnology industry cluster with cutting-edge infrastructure, facilities and services for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech-related manufacturing companies and organizations from other sectors in the industry.

DuBiotech is advised by an independent steering committee on scientific, business and ethical matters.

In co-operation with global research leader, RTI International, DuBiotech is developing comprehensive regulations that address all aspects of biotech activity.

ERC awarded Dubiotech contract
CONSTRUCTION UAE
19 May 2006

The local Emirates Road Contracting (ERC) has been awarded the estimated AED 125 million ($34 million) infrastructure package for the Dubiotech development near Emirates road.

The 14-month contract covers the construction of the project’s internal road network and the installation of services across the 190,000-square-metre site.

Dubiotech, part of Dubai Holding, plans to issue tenders for two of the development’s building packages later this year. Documents will be issued in July for a laboratory complex with a built-up area of 32,500 square metres and an 18-storey twin-tower headquarters building with a built-up area of 57,000 square metres. Parsons International of the US is the infrastructure consultant. A US joint venture (JV) of Parsons and CUH2A is the design consultant for the laboratory, and a US/German JV of CUH2A and Kling Consult is the consultant for the headquarters (MEED 10:2:06).

Dubiotech aims to become a biotechnology hub. It will promote research with biotech firms and international academic institutions, and attract drugs companies with its intellectual property legislation.

R

it's impossible to have a project without a tower, right?

great to see this one taking off now though

any pics or renderings of the project....although I assume it wouldn't look special considering it's a research facility, but then again it is Dubai so....

DuBiotech begins construction on USD400 million biotechnology cluster

The Dubai Biotechnology and Research Park (DuBiotech), earlier this week, broke ground on the first phase of its USD400 million (AED 1.47 billion) biotechnology industry cluster which will include its laboratory complex and headquarters.

http://www.ameinfo.com/images/news/6/27706-dubiotech.jpg
DuBiotech headquarters.

Dr. Abdulqader Al Khayat, Executive Director of DuBiotech and executives from TECOM Investments including Abdullatif Al Mulla, CEO and George Mushahwar, COO, attended the groundbreaking ceremony.

The laboratory complex will be complete by December 2007 followed by the headquarters in September 2008.

that thing must be HIGHRISE and it looks awesome :eek:

we need another rendering and open a thread.

we will as soon as we have some more info... it does look promising

lol
and i thought there won't be any towers in dubiotech

but this one indeed looks very promising

DuBiotech Research Park
Dubai, United Arab Emirates,
Allard Meine Jansen Architect


http://www.vizlab.it/works/p3_05_dubai/img/01_big.jpg

http://www.vizlab.it/works/p3_05_dubai/img/02.jpg

http://www.vizlab.it/works/p3_05_dubai/img/03_big.jpg

http://www.vizlab.it/works/p3_05_dubai/img/04.jpg

is this for real :eek:

I doubt it

is this for real :eek:

I found it on a website of a 3d rendering company. Doesn't have more information than what I posted.

Build it now! :D

Talk about an innovative design. I like the honeycomb pattern. These could be supertalls!

Setting the stage for development

http://www.gulfnews.com/images/06/09/01/02_bz_abdul_qader_alkhayat_4.jpg
Dubiotech will be built in phases on a 300 hectare area located close to the Dubailand project. Abdul Qader Al Khayat provides an update on the project to Gulf News.

Set up last year as an industrial cluster under the Dubai Technology and Media Free Zone Authority, Dubiotech will be built in phases on a 300 hectare area located close to the Dubailand project. It will offer custom-made research and development facilities. It is hoped the zone will attract scientists and biotechnology companies.

Gulf News: What is the current status of Dubiotech?
Al Khayat: We have started building the basic infrastructure. It will be completed in June or July next year. Our approach is to develop infrastructure facilities like roads and telecommunications network first.

We are hoping to start construction of the lab building in two months. It will be ready in two years from now. The headquarters building is in the final design stage, with construction expected to start in four months.

In terms of legal infrastructure, we will have most of the basic regulation completed by the end of this year. The laws will be available both in English and Arabic. RTI (Research Triangle Institute) of the US is our consultant and advisor.

On the business side, we have already licensed around 16 companies. We are in the process of getting 10 more companies.

Gulf News: When will Dubiotech be ready?
Al Khayat: The companies that we have licensed are already operating from different locations. Some are operating from the DIFC, some are located at Academic City. We are looking at early 2008 when companies will start moving to the main location.

Gulf News: Is Dubai's own lack of work in the field a handicap?
Al Khayat: Biotechnology has become a kind of resolution. Dubai recognises this technology will become a frontier for business and economy in the future.

The idea behind establishing a biotech free zone is to capitalise on this science and develop an industry based on it. This is really a challenging task and we recognise there are so many difficulties to execute such a project.

Our strategy is to establish the basic know-how through collaboration. We have an understanding with the University of Sharjah to look at programmes that will be more geared towards research.

We are talking with several international universities to establish graduate programmes in biotechnology. These are long-term plans for establishing the science base and manpower needed for such technology.

We want to establish joint venture start-ups and medium-size companies and invite them to participate in technology transfer.

Gulf News: Which countries would you collaborate with?
Al Khayat: India is focusing on biotechnology and has made big progress in this area. China is also doing significant work and spending a lot on R&D. We are open to different collaboration opportunities.

We are not limiting ourselves to certain regions. We look at opportunities that will be beneficial for the UAE.

We have already established some contacts in Germany, we are looking to meet a group from Singapore soon.

DuBiotech aims for global ‘green’ rating on complex

http://www.itp.net/pictures/news/138p4200.gif
DuBiotech is set to become one of a growing number of ‘green’ projects in the region seeking LEED status.

The Dubai Biotechnology and Research Park (DuBiotech) is set to become the first multi-building development in the UAE that will meet global environmental benchmarks.

It also becomes the first free zone in the region to adopt standards set by Leadership in Energy and Environmental Design (LEED) – a leading international rating system for green buildings.

Dr Abdulqader Al Khayat, executive director, DuBiotech, said: “Across the world, corporate organisations are waking up to the need to build more sustainable businesses.

“It is important that we commit to practices that ensure our infrastructure is environmentally sound. The adoption of such policies is essential to secure our long-term economic development,” he added.

According to its new ‘green’ policy, the entire DuBiotech complex, including its headquarters, laboratory buildings and pre-built units will be constructed according to international guidelines of sustainable development.

The buildings will be efficient in the use of energy, water, and materials and will have a high-quality indoor environment.
The heating and cooling systems, lighting and appliances in the buildings will be highly energy efficient. Air-conditioning tonnage will be reduced with floor units and solar shading.

The buildings will also incorporate water-efficient technology.
DuBiotech buildings will undergo the LEED certification process, which will involve evaluation of diverse criteria, including energy and water efficiency, indoor environmental quality, sustainable sites and materials, and resources. Once certified, DuBiotech’s complex will be one of the largest ‘green’ buildings in the world.

The adoption of ‘green’ practices will bring considerable benefits for DuBiotech. A comfortable and healthy environment will help boost employee productivity. Increased energy and water-efficiency will reduce operating costs.

The Dubai Biotechnology and Research Park was announced in February 2005 to create an advanced technical and community infrastructure to accelerate the growth of the life sciences industry in the region.

Established under Tecom Investments, DuBiotech’s facilities will be built in phases on a 200ha area close to Dubailand. Infrastructure work has begun and is scheduled for completion by mid 2007.

DuBiotech finalizes regulatory framework

Dubai Biotechnology and Research Park (DuBiotech) announced today the completion of its comprehensive regulatory standards for the Biotechnology and Pharmaceutical industry.

DuBiotech has partnered with the Research Triangle Institute International (RTI) to develop the park's comprehensive Codes of Practice (COPs) based on international best practices covering all activities related to Clinical Research and Clinical Trials, Manufacturing and Environment, Health and Safety. The COPs developed are in-line with those of the US Food and Drug Administration (FDA), World Health Organization (WHO), Occupational Safety and Health Administration (OSHA), European Agency for the Evaluation of Medicinal Products (EMEA), and the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

Dr Abdulqader Alkhayat, DuBiotech's Executive Director, said: 'We are proud to announce the completion of the regulatory framework, which will harness Biotechnology's potential to improve health, enhance quality of life and promote a sustainable economy. In developing this critical document, we found an ideal partner in RTI.'

Al Khayat added: 'In developing this regulatory framework, we have taken into consideration the Shar'iah law, and by completing it we have taken a crucial step towards providing a secure environment for research and innovation.'

Recognizing Research and Development (R&D) as a core component of the park's activities, DuBiotech and RTI have meticulously created COPs governing all aspects of R&D. The research component of the COPs outlines the research governance structure, ethical and environmental compliance requirements, good laboratory practices, Institutional Review Committee (IRB) responsibilities, investigator's obligations and informed consent procedures thus assuring governance and compliance throughout the R&D value chain.

The regulatory framework also includes COPs governing Manufacturing activities in the park. Good Manufacturing Practices (GMP) as well as Good Laboratory Practices (GLP) are described focusing on pharmaceutical, bio-pharmaceutical and sterile medicinal products manufacturing. Compliance and Accreditation requirements of Cord Blood Banks are also included in DuBiotech's regulatory framework.

DuBiotech's regulatory framework also contains COPs on Environment Health and Safety addressing all the potential risk factors related to the park's core activities and specifically dealing with prevention and control of integrated pollution, handling of hazardous chemical and biological agents, health and safety at work, as well as waste management.

Announced in February 2005, the Dubai Biotechnology and Research Park (DuBiotech) is a cluster dedicated to the Biotechnology and Pharmaceutical industry, set within a free zone infrastructure. DuBiotech aims to set up a biotechnology industry cluster with the appropriate infrastructure, facilities and service for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech and pharmaceutical manufacturing companies.

The Foundation for Research and Innovation (FRI), which will be the main arm focusing on government funded R&D, will initially focus on research related to genetics, plant biotechnology encompassing food and agricultural biotech, environmental biotech and equine-related biotechnology, drug discovery, stem cell research, infectious diseases and forensic research.

very nice. I wish we had more 'green' towers in Dubai. It would save a lot of energy in the long run but more importantly.... The double layer of cladding on this type of towers looks extremely cool!

I would say: START BUILDING IT TODAY!

this was in today's papers:

http://i17.tinypic.com/6fzxt1c.jpg

still quite good tho.

R

any news or pix?? the completion date??

Dubiotech, Dubai’s biotechnology and research park, will be the base of a new bio-pharmaceutical firm formed through a joint venture between Indian biotechnology major Biocon and Abu Dhabi-based pharmaceutical manufacturer Neopharma.

The new company, called Neobiocon, is a 50:50 joint venture with a total investment of Dh100 million over the first three years.

Its aim is to provide affordable life-saving drugs to patients in the UAE.

Speaking at the launch yesterday, Rakesh Bamzai, marketing president of Biocon, said: “Neobiocon will be committed to developing a range of products for debilitating disease segments.

“Obesity, diabetes, hypertension and high levels of cholesterol are interlinked and go hand-in-hand. Biocon’s research addresses all these segments. Neobiocon will offer products that cater to lifestyle disorders and oncology, and we will also produce immunosuppressant drugs.” The company’s 50,000 square foot facility at Dubiotech is to be operational in about three years.

The venture is part of Biocon’s drive to more than double its business footprint in the Middle East over the next five years, according to the company’s Chairman and Managing Director Kiran Mazumdar-Shaw.

“Currently the Middle East accounts for a little under 10 per cent of our business,” she said yesterday. “Through this partnership we would like to get up to between 20 and 25 per cent in the next five years.

“In the first year we will probably have a basket of two or three diabetes products, increasing to five or six products in five years time. The total investment value in Neobiocon in the first three years will be Dh100m, and it is a 50:50 venture between us and Neopharma.

“Our long-term vision is to ensure that the country [the UAE] is self-sufficient in biopharmaceutical products.

“Obviously, the US offers the biggest market opportunities at the moment – it accounts for 60 to 70 per cent of our business.” Neobiocon represents the region’s foray into developing and marketing biopharmaceutical products in areas such as oncology, diabetes, cardiology and new generation immunosuppressant drugs.

Biotherapeutics for cardiovascular diabetes and oncology segments represent the fastest growing class of drugs in the $5bn (Dh18.4bn) GCC pharmaceutical market, according to research.

Dr Abdulqader Al Khayat, executive director of Dubiotech, said: “It is a privilege to host the initiative by Neopharma and Biocon.”

http://img503.imageshack.us/img503/6007/31072007012002008lk9.jpg

Nice sth is happening here finally.. took some time..

Bel Hasa wins dual towers contract from Dubiotech
CONSTRUCTION UAE
7 Sep 2007
The local Bel Hasa Engineering & Contracting has been awarded the estimated AED 400 million ($108 million) contract to build a headquarters for Dubiotech, which is developing Dubai Biotechnology & Research Park.

The park is located between Emirates and Shaikh Zayed roads. The contract involves the construction of two 18-storey office towers on a common podium. The total built-up area is 57,000 square metres.

The building’s design is based on DNA, with slabs running along the sides of the buildings representing DNA strands of different sizes. The design won an award for sustainability earlier this year.

The park will also include an animal reserve spread over 50,000 square metres, where indigenous animals will be free to roam.

The local Emirates Road Contracting is working on the estimated AED 125 million ($34 million) infrastructure package, after being awarded the contract in May last year.

Parsons International of the US is the infrastructure consultant. A US/German group of CUH2A and Kling Consult is the consultant for the headquarters (MEED 19:5:06).

Dubiotech is part of the government-owned Dubai Holding.It aims to become a biotechnology hub, promoting research.

R

any update for construction site .....;)

The park will also include an animal reserve spread over 50,000 square metres, where indigenous animals will be free to roam.

So that is the new location for the Dubai zoo :lol:

DuBiotech commences HQ
United Arab Emirates: Sunday, November 04 - 2007 at 13:59
The Dubai Biotechnology and Research Park (DuBiotech) has broken ground on its 22 storey headquarters, Bio HQ, and the Nucleotide Complex laboratory buildings, both of which are part of the project's first phase. The 600,000 sqft headquarters has been designed by CUH2A and should be completed by May 2009. The Nucleotide Complex will be ready by September next year.

http://img339.imageshack.us/img339/542/ncckd5.gif

NCC Urban Infrastructure Limited has launched a Dh1.5 billion ($408 million) mixed-use freehold development in Dubai.

The company is a subsidiary of India's Nagarjuna Construction Company Limited (NCCL).

NCC Harmony, an iconic twin tower project of 2.3 million sq ft built-up area will come up at Dubai Biotechnology and Research Park (DuBiotech), the free zone dedicated to biotechnology, pharmaceutical and life sciences.

The project is the company’s first venture in Dubai. The project is strategically located at the heart of New Dubai, in close proximity to Arabian Ranches, Dubailand and prominent shopping centres.

NCC Harmony is backed by the expertise of NCCL (NCC Urban India), an ISO 9001-14001-18001 certified group rated by Forbes Asia among the ‘Best Under Billion’ listed companies in Asia Pacific (2005). With an annual turnover of Dh3 billion, NCCL is one of the largest construction groups in India.

Construction of NCC Harmony has already begun with contracts for excavation, piling and shoring being awarded to Dutch Foundation and Concrete Processing Co. Tecom Investments are the master developers of DuBiotech.

Slated for completion in May 2010, the development will encompass two 32-level towers – one residential and one hotel apartment – with luxurious studio, single-bedroom and double-bedroom apartments offering fully-equipped accommodation to those working in New Dubai locality.

The project, to be fully sustainable and environmental friendly, will be equipped with a health club, spa and pool area, spread over 53,000 sq ft making it one of biggest health facilities in Dubai till date.

Announcing details about the project, Narayana Raju Alluri, managing director of NCC Urban and director on NCCL board, said: “It is a matter of great privilege for us to announce our first project in Dubai. NCC Harmony is ideally situated at the entrance of DuBiotech – an upcoming business locality in close proximity to dedicated media and IT hubs -- Dubai Media City and Dubai Internet City and the emerging New Dubai. It is among the first purpose-built projects to offer residents a luxurious lifestyle at an attractive financial package.”

In his comments, Dr Abdulqader Alkhayat, executive director of DuBiotech, said: “The NCC complex with its serviced apartments will cater to the requirements of our business partners and significantly benefit regular corporate visitors to DuBiotech. NCC Urban will complement our overall infrastructure facilities, reiterating our keenness to provide a holistic offering to investors in the park. As DuBiotech continues to grow, we will strive to offer additional value-added service to our partners.”

^^ Is this a reasearch park or a Hotel ?

who gives a crap what the building looks like, its what's inside that maters !!

the more i read about this project, the more iam convinced its yet just another hotel / service appartment, except its being brandad as a "reasearch lab" who are they kidding?

^^ Is this a reasearch park or a Hotel ?

who gives a crap what the building looks like, its what's inside that maters !!

the more i read about this project, the more iam convinced its yet just another hotel / service appartment, except its being brandad as a "reasearch lab" who are they kidding?

What are you talking about? Both the HQ and Nucleoid complex has begun and those are following the purpose of the park. This hotel and apartments projects is a part of the mixed use part in the outer section found in the masterplan on http://www.dubiotech.com/

Obviously the mixed use portion of this development is far from too much and will only make out a small, but very neccesary part, of such a huge project.

DuBiotech breaks ground for 22-storey HQ and laboratory buildings
Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments, yesterday broke ground for the construction of its 22-storey headquarters - Bio HQ, and the state-of-the-art laboratory buildings - the Nucleotide Complex.
United Arab Emirates: Sunday, November 04 - 2007 at 12:48 PRESS RELEASE

http://www.ameinfo.com/images/news/3/47723-bio.jpg
Bio HQ.

The two buildings are part of Phase I of the overall project that is scheduled for completion in 2009.

Abdullatif Al Mulla, CEO, TECOM Investments, Dr. Abdulqader Alkhayat, Executive Director, DuBiotech, and senior officials attended the groundbreaking ceremony for the park, which has successfully completed its basic infrastructure works, including roads and utility services.

The 600,000 sq ft headquarters has been designed by CUH2A, a recognised leader in designing facilities for science and technology organisations. DuBiotech recently won the Design and Sustainability Honour Award from the American Institute of Architects (AIA) New Jersey Chapter for the technologically complex headquarters.

Poised to be one of the world's largest green buildings, the Bio HQ building was chosen for its 'new regional vision' and its 'refreshing and functional design' employing 'new moves to address environmental concerns'.

Dr. Abdulqader Alkhayat, Executive Director, DuBiotech, said: 'Our initiative to develop sustainable buildings matches our commitment to be a socially and environmentally responsible organisation'.

'As part of TECOM's overall strategy, all buildings at DuBiotech are to be classified as LEED certified 'green' buildings. This extends not only to the headquarters and laboratory complexes, but to the manufacturing and community service buildings that will be included in the park.'

Dubai Properties is the project manager for both the projects. Belhasa Engineering and Contracting and Al Sahel Contracting have been appointed as contractors for the Bio HQ and the Nucleotide Complex respectively.

Bio HQ's unique design will reflect DNA movement in a gel electrophoresis, a technique commonly used in the life science industry. The slabs running along the sides of the buildings will represent DNA strands of varying sizes, migrating towards each other in a gel matrix. Hosting the regional sales and marketing offices of multinationals and start up companies specialising in life sciences, the headquarters will be completed by May 2009.

The Nucleotide Complex, enabling companies to conduct laboratory-based research and analysis without the need to build their own dedicated facilities, is scheduled for completion by September 2008.

Currently, 28 companies, licensed by DuBiotech, are completely operational. The park is working closely with the UAE Ministry of Health, the Dubai Health Authority, and other relevant regulatory bodies to further develop the life sciences industry in the country.

DuBiotech offers the complete value chain to help companies set up their operations. In addition to pharmaceutical and biotechnology companies, it aims to provide the necessary infrastructure for all entities involved in the life sciences industry, including the agricultural, environmental, and marine biotechnology sectors. The park also provides support services for R&D, manufacturing and commercial facilities.

Merck Serono Middle East opens regional office at DuBiotech in Dubai
H. E. Humaid Al Qutami, UAE Minster for Health, today attended the inauguration of Merck Serono Middle East's new regional office at the Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments.
United Arab Emirates: Tuesday, November 13 - 2007 at 13:34 PRESS RELEASE

http://www.ameinfo.com/images/news/2/48332-dub.jpg
Dr. Abdulqader Alkhayat, Executive Director of DuBiotech with Elmar Schnee, Member of the Executive Board of Merck KGaA and Head of Merck Serono, at the press conference today in Dubai to announce the launch of Merck Serono's regional headquarters at the biotechnology cluster.


Merck Serono is a division of Merck KGaA, the German pharmaceutical and chemical company with operations in 61 countries across the world. The 700-square-meter new regional office will accommodate 40 employees and cater to Merck Serono's operations in the Middle and Near East, spanning 12 countries, serviced by more than 150 sales representatives.

Elmar Schnee, Member of the Executive Board of Merck KGaA and Head of Merck Serono; Abdullatif Al Mulla, CEO, TECOM Investments; Dr. Abdulqader Al Khayat, Executive Director of DuBiotech, and other senior officials attended the ceremony.

Schnee said:
'With our operations in the Middle East dating back to the 1970s, the opening of Merck Serono's new headquarters at DuBiotech underscores our rich relationship with the region. As a leader in the biotechnological drugs market, our presence at DuBiotech's stimulating high-tech environment gives us one more reason to celebrate a global milestone that allows us to continue bringing our leading therapies to this region.'

Dr. Al Khayat said: 'Hosting regional offices for biotech pioneers such as Merck Serono confirms our status as a premier destination for global brands. The 300-hectare dedicated free zone already hosts several industry leaders, and serves as an ideal platform for international entities seeking to extend their footprint in the Middle and Near East. Our privileged partnership with Merck Serono will serve to enrich the biotechnology sector in the region and further contribute to the industry's development.'

Uloff Muenster, Vice-President of Merck Serono's Commercial International/Intercontinental business, said: 'Today, Merck Serono's operations exist in every country in the region, offering patients a wide range of innovative leading products. Understanding the Arab culture helps us learn the requirements of the doctors and patients, our main assets that have enabled us to outperform others in all therapeutic areas.'

Tim Kneen, Managing Director Merck Serono Middle East, said: 'Merck Serono Middle East is a regional leader in specialized therapeutic areas. We have always offered treatment that provides tangible benefits to patients, while exceeding physicians' expectations with life-saving drugs. The investment in the new regional office is a reflection of our determination to expand business in the Middle East through offering patients our unique therapies.'

Some of Merck Serono's leading pharmaceutical products include Glucophage, the only recommended first-line treatment worldwide for patients with type-2 diabetes; Erbitux, a targeted therapy for the treatment of colorectal and head & neck cancers; and Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis.

ERGOMED Locates Regional Headquarters at DuBiotech in Dubai

DUBAI, United Arab Emirates & FRANKFURT--(BUSINESS WIRE)--ERGOMED Group, the specialized international clinical development company, and the Dubai Biotechnology and Research Park (DuBiotech) today announced ERGOMED will locate its Middle East and India headquarters at the life sciences park.

ERGOMED is the first contract research organization (CRO) to establish a base at DuBiotech. Founded in 2005, DuBiotech, a member of TECOM Investments, is one of the fastest growing biotechnology clusters in the world. Spread over 300 hectares, it serves as an ideal platform for leading global biotechnology brands to establish their footprint in the region.

ERGOMED provides a full suite of clinical trial services to biotechnology companies. The Company, which specializes in oncology, neurology and immunology, also offers consultancy and co-development approaches to biopharmaceutical drug development.

Dr. Miroslav Reljanovic, CEO of the ERGOMED Group, said: “We see this expansion as a strategic move, with the Middle East and India now emerging as truly attractive regions for biotechnology. As with our co-development business model, ERGOMED has once again become a pioneer in the geographic broadening of a rapidly changing industry. DuBiotech offers the ideal environment to locate our regional headquarters and our presence in the park will gain us new business opportunities.”

Dr Abdulqader Al Khayat, Executive Director of DuBiotech said: “ERGOMED has a strong reputation in Europe for working with the biotechnology industry there. We are privileged to host this organization that will broaden the spectrum of companies operating here. ERGOMED will contribute to the development of clinical research and enable the UAE and the Middle East to compete strongly on the global platform.”

The Dubai Biotechnology and Research Park recently announced the completion of its comprehensive regulatory standards for the biotechnology and pharmaceutical industry, comparable with those in Europe and the US. Dubai’s favourable funding climate and regulatory environment has opened the doors for international biotechnology companies to establish their regional base in the state-of-the-art park.

Contract Research Organizations (CROs) such as ERGOMED are crucial service providers in the modern world of drug development and a necessary component in the growing Middle Eastern biotechnology industry. Prior to the 1990s, pharmaceutical and academic research institutions that were developing drugs usually conducted their own clinical trials. Since then, there has been a trend for global pharmaceutical companies to shift towards streamlining their operations.

As part of that process, many research capabilities have been outsourced and various phases of drug development have been directed to CROs instead. In 2005, US$14 billion of the US$56 billion that pharmaceutical and biotechnology earmarked for R&D was allocated to CROs. Market analysts predict this figure will grow to US$20 billion by 2010.

About ERGOMED Group

ERGOMED is a specialized international clinical development company offering contract clinical research and co-development partnerships to biotechnology and pharmaceutical companies worldwide in the fields of neurology, oncology and immunology. ERGOMED’s approach to clinical research ensures effective patient recruitment, reducing the time and costs of clinical trials and complementing the drug discovery capabilities of its customers and partners. The Company has a dual business model offering standard clinical trial management contracts and also co-development partnerships to share the risks and rewards of clinical development. ERGOMED is headquartered in Frankfurt, Germany, and has offices throughout Europe and in USA. For further information visit www.ergomed-cro.com

About DuBiotech

The Dubai Biotechnology and Research Park (DuBiotech) was launched by UAE Vice President and Prime Minister and Ruler of Dubai His Highness Sheikh Mohammed bin Rashid Al Maktoum, as part of Dubai’s 2015 vision to establish a knowledge based economy. Biotechnology is thriving and has thus been identified by the Government of Dubai as a major target area for economic development. In keeping with this vision, DuBiotech promises to be the regional centre of excellence for biotechnology. The Park will service the entire industry, ranging from small incubators to regional offices of key biotechnology and pharmaceutical companies, to manufacturing plants. DuBiotech will have a regulatory framework, modeled on international best-practices. With this regulatory framework in place, all activities related to biotech development will be overseen and monitored, to ensure health & safety and streamlined operations for the park. In addition, a Steering Committee made up of prominent regional and international scientists will offer guidance to DuBiotech. The Committee will facilitate full regional involvement and provide direction to ensure that in this fast-paced industry, DuBiotech is able to respond to all changes in the most appropriate manner.

DuBiotech Research Park
Dubai, United Arab Emirates,
Allard Meine Jansen Architect


http://www.vizlab.it/works/p3_05_dubai/img/01_big.jpg

http://www.vizlab.it/works/p3_05_dubai/img/02.jpg

http://www.vizlab.it/works/p3_05_dubai/img/03_big.jpg

http://www.vizlab.it/works/p3_05_dubai/img/04.jpg

woooooooow:nuts::nuts:

Deyaar launches Mirar at DuBiotech

http://business24-7.ae/SiteLists/ArticlesTempPhotoGallery/5_26_2008/ArtclDtaPg_761839884886481898007696eb53e24c_2.0.jpg

Deyaar Development yesterday launched Mirar Residences, a three-tower residential project in Dubai Biotechnology and Research Park (DuBiotech).

The three 19-storey towers are scheduled for delivery in the fourth quarter of 2010, with construction already under way, according to a company statement.

"Fresh from the success of our recent Oakwood Residency project in the International Media Production Zone, which sold out within a day of its launch, we expect to experience another swift sell out with this new offering", said Saeed Al Qatami, Deyaar's Managing Director for UAE Business.

"At Deyaar, we have consistently been at the forefront of new high-potential master developments. Mirar Residences is one of the first residential offerings in the centrally located DuBiotech park. Our customers will again reap the rewards of Deyaar's strategic foresight and expertise by becoming one of the first proud homeowners in this high-potential master development. "

The company's latest offering – Mirar Residences – offers 414 one, two and three-bedroom apartments, some of which offer maid's accommodation. Set amidst a modern residential hub within DuBiotech, Mirar Residences will comprise luxurious recreational facilities, including rooftop swimming pools, modern gymnasiums, ample parking space and high-speed internet connectivity.

The project will also be served by the second stage of the Dubai Metro.

"Deyaar has a track record of setting quality and value standards in all its ventures, and Mirar Residences will be no different. Deyaar is committed to growing its presence across Dubai's master planned communities, while maintaining the high levels of customer service and product excellence that has seen all its projects prove hugely attractive to both investors and end-users," Al Qatami said.

DuBiotech is a master development dedicated to creating an advanced technical and community infrastructure to accelerate the growth of the life sciences industry in the region.

Located close to Dubailand, the free zone hosts state-of-the-art laboratories, as well as manufacturing units, core research facilities, and premium residential and office spaces.

Dr Amina Al Rustamani, Chief Executive Officer, Tecom Business Parks, said: "As a premier biotechnology park, DuBiotech is committed to building a city where professionals, individuals and families thrive as a community that is dedicated to the relentless pursuit of knowledge.

"We are delighted Deyaar has chosen to participate in the growth story of DuBiotech, which has already evolved as a hot spot for leading global brands from niche sectors."

Buyers at Mirar Residences can avail of financing from a range of home finance providers, including Abu Dhabi Commercial Bank, Amlak Finance, Dubai Islamic Bank, RAK Bank and Tamweel.

With the launch of Mirar Residences, Deyaar continues to comply with all best practices pertaining to the real estate industry such as escrow account law and registration with the Dubai Land Department.

Deyaar's Mirar Residences sold out

Deyaar Development said yesterday that it has sold out Mirar Residences, its three-tower residential project that was launched at DuBiotech on Tuesday.

The project launch was attended by an overwhelming number of investors and end users keen to purchase units within Deyaar's latest real estate undertaking.

"Our customers recognise Deyaar has a strong track record of meeting commitments and being transparent. In addition, Mirar Residences is another pioneering offering in a new high potential master development, DuBiotech, where investors will be rewarded for getting in first," said Saeed Al Qatami, Deyaar's Managing Director for UAE Business.

"Today's endorsement continues to build on the company's impressive record of units being snapped up within hours."

http://i33.tinypic.com/2z5qa78.jpg
http://i37.tinypic.com/10ekhsx.jpg
http://i37.tinypic.com/351v8ex.jpg

http://i38.tinypic.com/a4a2k8.jpg

http://i38.tinypic.com/4rojsh.jpg
http://i38.tinypic.com/34dmoba.jpg
http://i34.tinypic.com/jsyqma.jpg

http://i36.tinypic.com/10cm3qv.jpg

Great updates 234sale ...

Video to upload as well.. Roads are 100% finished.

Do we have seperat threads for these great towes here??

I think all of them inside this thread .

We should open new ones for every single tower !!

so r we not posting enitre articles becuase we culd get sued??? so if u do post an article put a link??? is that rite???

Omniyat Properties to reveal over Dhs10bn new projects at Cityscape Dubai 2008

Omniyat Properties, the most innovative private property development company in the Middle East, will showcase their latest plans and unveil projects valued at over Dhs10bn at Cityscape Dubai 2008.

The Fusion project is in final design stage and is planned as an urban mixed-use development in the prestigious DuBiotech, the first science and business park in the Middle East. The Fusion is designed to be an expression of Omniyat's development of a new life model which integrates home, life and leisure within a single, seamless environment.

http://www.ameinfo.com/170384.html

R

^^ Yes, that's fine.
In fairness I don't think it's a problem but when 100s of articles are posted in their entirety without links then who knows.

Dubai's sustainable star

http://static.worldarchitecturenews.com/project/uploaded_files/10413_MegaStar_01.jpg

Perkins Eastman combines sustainability and innovation to design MegaStar
The MegaStar mixed-use development is a state-of-the art, 100,000 sq m facility in the DuBiotech Research Park—a world-class, 2.8 million sq m global biotechnology and research park located in Dubai, UAE.

Realizing biotechnology is one of the greatest intellectual investments that exist in the world, international architecture and design firm Perkins Eastman sought to create an environment where everyone in the biotech industry can coexist, collaborate and exchange ideas. As a large and dynamic business cluster and hospitality venue, the Megastar development contains a 280-room hotel, 550 serviced apartments, a ballroom and meeting facilities, and a retail shopping mall. Bringing together these elements creates a rich environment for networking and collaboration, providing space for a mix of key players of the biotechnology and pharmaceutical industry, as well as drug manufacturers and industry specific experts.

The tower—the signature element of the project—creates a landmark entrance to the research park and the development itself. The building and its undulating overtones is a mixture or innovative technology and sustainable design that not only mandates recycling on the premises and is powered by alternative energy. Other sustainable elements include passive solar strategies throughout the exterior and interior of the building including planted terraces on the tower façade, a green roof, louvers, recessed balconies, and a double-skin to reduce heat gain. The double-skin also reduces light pollution and promotes natural air circulation throughout the building.


http://www.worldarchitecturenews.com/index.php?fuseaction=wanappln.projectview&upload_id=10413

25/June/2009

Mirar Residences(Dubiotech)

http://i44.tinypic.com/2ug1aa0.jpg

http://i42.tinypic.com/15nln3a.jpg

http://i40.tinypic.com/212aeys.jpg

25/June/2009

132/11kV substation (Dubiotech)

http://i41.tinypic.com/2w58sad.jpg

http://i44.tinypic.com/aykbco.jpg

We should open new ones for every single tower !!

maybe you should do it:)

25/June/2009

Three Towers (Dubiotech)

http://i43.tinypic.com/ohjy0z.jpg

http://i40.tinypic.com/2h34dxt.jpg

http://i40.tinypic.com/3029x0g.jpg

http://i43.tinypic.com/j5dt05.jpg

25/June/2009

Headquarters Complex (Dubiotech)

http://i43.tinypic.com/vqk0hs.jpg

http://i39.tinypic.com/2nqts1u.jpg

http://i39.tinypic.com/okx1c5.jpg

http://i40.tinypic.com/2hsc2dd.jpg

http://i40.tinypic.com/2q2jqqq.jpg

http://i39.tinypic.com/331dq2e.jpg

http://i44.tinypic.com/2w4if0p.jpg

http://i39.tinypic.com/29d8veo.jpg

http://i43.tinypic.com/2zqh6jp.jpg

25/June/2009

Dubiotech

http://i40.tinypic.com/axi4uc.jpg

25/June/2009

Headquarters Complex (Dubiotech)


Any information about the height??

The 12,000-square-foot laboratory, which will become operational later this year, will occupy the entire ground floor area in one of the four wings at the new Nucleotide Complex, the technology-intensive laboratory building in the life sciences cluster.

http://www.dubiotech.ae/index.php?option=com_content&task=view&Itemid=38&id=160

Dubai- Dubai Biotechnology and Research Park (DuBiotech), a major life sciences hub in the Middle East and a member of TECOM Investments, today announced it has become a member of the Federation of Asian Biotech Associations (FABA).

FABA is a non-profit international organization established in 2005. Founded with the objective of creating a common platform for the development of biotechnology, it also aims to promote and safeguard the overall interests of biotechnology as a science and profession, as well as that of industry professionals, entrepreneurs, industries and academic institutions of Asian countries.

The FABA membership will help DuBiotech explore fresh business opportunities, as well as cooperate and collaborate with biotechnology companies and institutions across Asia.

The UAE, through DuBiotech, has become the 19th member state of FABA. Other major Asiatic countries that have their biotechnology industry represented in FABA are China, India, Japan, Saudi Arabia, Turkey and Malaysia.

FABA also enjoys the support of several Asian and non-Asian biotech organizations such as Biocat (Catalonia - Spain), European Federation of Biotechnology, Bioindustry Park Canavese – Italy, The Federation of Andhra Pradesh Chambers of Commerce and Industry (FAPCCI) in India, the Confederation of Indian Industry (CII), the Russian Biotechnology Society, Maryland-India Business Round Table (MIBRT) and the Association of German Biotechnology Companies (DECHEMA).

Dr Marco Baccanti, Executive Director of DuBiotech, said: “The membership of the Federation of Asian Biotech Associations will help us explore collaborations in the region and increase awareness of the advantages that emerging Asian biotech companies can gain from the access to the wide range of services and assets offered by the DuBiotech cluster.

“DuBiotech has firmly established itself as a globally recognized centre for the life sciences industries, and joining prestigious organizations such as FABA will further strengthen its role as an industry pioneer in the region.”

Dr. B. S. Bajaj, Secretary General, FABA, said: “We are extremely happy that the Federation of Asian Biotech Associations and Dubai Biotechnology and Research Park have entered into an agreement to work together for the development of the industry in Asia. We believe this will lead to an Asian biocluster and result in closer networking, particularly between the UAE and India.

“The establishment of FABA chapter in the UAE will help facilitate the continuous exchange of information on biotechnology development that will eventually bring enormous benefits for both the countries.”

According to recent research, the GCC healthcare services sector will witness major improvements in the quality of deliverables and in achieving competitiveness on a global scale. The region’s endeavour to set up integrated healthcare facilities in the form of medical cities and hubs, coupled with continuous improvement in technology and infrastructure, are expected to significantly improve the availability and quality of healthcare services in the region.

Biotechnology, which took off as a highly specialised scientific stream, is now at the heart of all biology and clinical therapy. With prestigious partners, including some of the world's top pharmaceutical/biotechnology companies such as Pfizer, Genzyme and Merck Serono, DuBiotech is positioned to significantly transform biomedical research and clinical therapy in the Middle East.


..................................




DuBiotech Announces Partnership with Swiss Biotech Association
Image

Dubai Biotechnology and Research Park (DuBiotech), the major life sciences hub in the Middle East and a member of TECOM Investments, announced it has signed an agreement with the Swiss Biotech Association to promote collaboration between the two organisations.

The agreement was signed by Dr Marco Baccanti, Executive Director of DuBiotech, and Domenico P. Alexakis, CEO of the Swiss Biotech Association, at an event hosted by Christian D. Watts, Diplomatic Counsellor and Regional Director for the Swiss Trade and Investment Promotion - IMEA. The event was also attended by Peter Harradine, President of Swiss Business Council, and representatives of the major biotechnology companies at the life sciences cluster in Dubai.

In addition to collaboration between the two biotechnology organisations, one of the initiatives under the agreement includes a campaign to raise awareness among the Swiss biotechnology and medical technology companies about the Middle East's growing healthcare market and the benefits offered by DuBiotech as a life sciences free zone.

Dr Marco Baccanti, Executive Director, DuBiotech, said: "Considering the strategic importance and the technology advancement of the Swiss biotechnology and medical technology sectors, and the benefits the DuBiotech platform offers to these industries, the agreement is an ideal move to ensure mutual advantages to the UAE and Swiss biotechnology companies."

Domenico P. Alexakis, CEO of Swiss Biotech Association, said: "We are actively supporting all our 183 members to develop their business opportunities. With the collaboration between DuBiotech and the national industry association, the awareness level will increase and generate additional value for the industry."

The Swiss Biotech Association's members are well connected to a cluster of 400 Swiss medical technology companies. The association will offer all these companies an opportunity to participate in seminars in the Middle East that will be co-organised by DuBiotech and the Swiss Biotech Association.

Currently, DuBiotech hosts some of the world's top pharmaceutical/biotechnology companies such as Pfizer, Genzyme and Merck Serono, and has firmly established itself as a globally recognised centre for the life science industries.



...............




Dubiotech Lab


http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_16a.jpg



http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_2.jpg


http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_3.jpg



http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_5.jpg



http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_6.jpg


http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_7.jpg


http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_9.jpg


http://desmena.com/wp-content/uploads/2009/05/cuh2a_dubiotech_1.jpg

nice buildings but is anyone working there?

Dubiotech
http://i46.tinypic.com/2ngd1f7.jpg

http://i50.tinypic.com/34r81aw.jpg

http://i46.tinypic.com/2dkisl2.jpg

Commercial/Office Buildings:

- The Nucleotide Lab Complex - Completed
- Dubiotech HQ Complex - U/C

Residential Buildings

- Three Towers - U/C
- Mirar Residences - Ground Work
- NCC Harmony - Ground Work

Mixed Use Buildings

- Unnamed Mixed Use Development - Ground Work

Other Buildings

- 132/11kV Substation - U/C

We should open new ones for every single tower !!

I don't think individual threads were/have been opened?

^^ no still not. I will do later.

Does anyone know what's happening with Mirar Residence? In March an article said it was a consolidation project-any news?

Firmenich, the world’s largest privately-owned company in the fragrance and flavor business, is pleased to announce the opening of its new affiliate in Dubai, United Arab Emirates.

The affiliate aims to strengthen Firmenich’s presence in the Gulf Region, enabling it to deepen its understanding of local consumers and markets, and to bring the region’s manufacturers, as well as multinational companies, its talent for creating unique fragrances and flavors adapted to local tastes.

“Firmenich flavors and fragrances create moments of happiness in the daily lives of billions of people around the world. Today, I wish Firmenich Dubai and our clients, much mutual success and the development of lasting relationships”, said Firmenich CEO, Patrick Firmenich.

Firmenich Dubai includes a team dedicated to Fine Fragrance sales, marketing and development for the Gulf Region. Similarly, Firmenich Flavors has a dedicated group that will focus on Flavor solutions for Sweet Goods, Beverages and Savory Food applications, tapping into worldwide marketing, sensory and technical teams to offer the highest level of expertise in applications like Juices and Dairy products, as well as Flavor solutions in areas like Citrus, Natural Ingredients and Taste Modulation.

The 500m2 of new office and laboratory facilities are located in the prestigious Dubai Biotechnology & Research Park (DuBiotech) - one of the Middle East’s major science and business parks. Like all Firmenich facilities, the center hasbeen developed with the highest industry standards in terms of product quality, safety, regulatory and sustainable business processes and practices.

Firmenich has Flavor and Fine Fragrance development centers and sales offices throughout Europe, Asia, Latin America and North America.

http://www.firmenich.com/filedownload.lbl?uid=a05954ee-d0ee-203a-028f-a20dac9120f3

hi
anyone know whats happening with Mirar Residence

Hi,
I am a lookin for a job in the biotechnology sector. I will complete my MSc in biotechnology this October from Kingston University London and I am desperately in need of a job. Could anybody tell me if Dubai is a good place to be looking for a job??? Also, I have no previous experience.. and nobody to guide me..
PLS HELP!!!
rhea...

https://lh6.googleusercontent.com/_tt5Fzuyo1nc/S8Ss5G5hvRI/AAAAAAAALWQ/ffzHIzfKyWg/s640/155.JPG


https://lh3.googleusercontent.com/_tt5Fzuyo1nc/S8Sto5-z6yI/AAAAAAAALXQ/xDvJpDHciCc/s720/blood%20lab%2063.jpg



https://lh6.googleusercontent.com/_tt5Fzuyo1nc/S8StBAf9F1I/AAAAAAAALWc/8xdjFGVlXCw/s640/158.JPG


https://lh3.googleusercontent.com/_tt5Fzuyo1nc/S8Ss09Rn0ZI/AAAAAAAALWM/VcdDJMfyAeE/s640/154.JPG

12/10/12
headquarters not progressing
http://farm9.staticflickr.com/8332/8082944636_bcd54aab12_b.jpg
Source: http://www.flickr.com/photos/carolblondon/8082944636/in/set-72157631811346661
High-Res: http://www.flickr.com/photos/carolblondon/8082944636/sizes/o/in/set-72157631811346661/

06/02/13
Dubiotech in the back, headquarters have no progress :(
http://img802.imageshack.us/img802/339/94201706.jpg
Source + High-Res: http://www.imageboxarabia.com/stock-photo/dubai-miracle-garden-9203.html
:cheers:

The project Dubai Biotechnology was a great step for Initiation ideal platform for the regional and international scientific community.

those Three Towers have made visible progress on the cladding, possibly work inside as well but not visible.

they are on the miracle garden photo above on the far right end. two of the towers are hidden, only one is visible on that pic.